AIM ImmunoTech Files Proxy Materials

TL;DR

AIM ImmunoTech dropped proxy docs, likely for shareholder votes. Keep an eye on governance.

AI Summary

AIM ImmunoTech Inc. filed a Definitive Additional Materials (DEFA14A) on December 5, 2024, related to its proxy statement. The filing includes a press release issued by the company on the same date. AIM ImmunoTech Inc. is a biopharmaceutical company focused on developing therapeutics for cancer and immune disorders.

Why It Matters

This filing indicates that AIM ImmunoTech is proceeding with corporate governance matters, which could involve shareholder votes on important company decisions.

Risk Assessment

Risk Level: medium — Proxy statements often precede significant corporate actions or shareholder votes that can impact stock price and company direction.

Key Players & Entities

• AIM ImmunoTech Inc. (company) — Registrant
• 20241205 (date) — Filing Date
• DEFA14A (document_type) — Filing Type
• 0001493152-24-048893 (accession_number) — Filing Identifier

FAQ

Key Financial Figures

• $15 Million — ominee Todd A. Deutsch AIM Highlights $15 Million+ Investment Partnership Between Activis
• $8 million — up has consistently demanded upwards of $8 million in expense reimbursement for prior fail

Filing Documents

• formdefa14a.htm (DEFA14A) — 58KB
• formdefa14a_001.jpg (GRAPHIC) — 6KB
• formdefa14a_002.jpg (GRAPHIC) — 335KB
• formdefa14a_003.jpg (GRAPHIC) — 353KB
• 0001493152-24-048893.txt ( ) — 1016KB

From the Filing

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material under § 240.14a-12 AIM ImmunoTech Inc. (Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required Fee paid previously with preliminary materials Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 On December 5, 2024, AIM ImmunoTech Inc. (the “Company”) issued a press release, a copy of which is attached hereto as Exhibit 1. Also on December 5, 2024, the Company issued the following materials, copies of which are attached hereto as Exhibit 2. Forward Looking Statements The materials attached contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking success seen to date does not guarantee that Ampligen will be approved as a treatment or therapy for any diseases or conditions. The Company urges investors to consider specifically the various risk factors identified in its most recent Annual Report on Form 10-K, and any risk factors or cautionary statements included in any subsequent Quarterly Report on Form 10-Q or Current Report on Form 8-K, filed with the U.S. Securities and Exchange Commission (the “SEC”). You are cautioned not to place undue reliance on these forward-looking the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Important Additional Information The Company, its directors and executive officers, Peter W. Rodino, III and Robert Dickey, IV, are deemed to be “participants” (as defined in Section 14(a) of the Securities Exchange Act of 1934, as amended) in the solicitation of proxies from the Company’s stockholders in connection with the Company’s 2024 Annual Meeting of Stockholders (the “Annual Meeting”). The Company filed its definitive proxy statement (the “Definitive Proxy Statement”) and a WHITE universal proxy card with the SEC on November 4, 2024 in connection with such solicitation of proxies from the Company’s stockholders. STOCKHOLDERS OF THE COMPANY ARE STRONGLY ENCOURAGED TO READ SUCH DEFINITIVE PROXY STATEMENT, ACCOMPANYING WHITE UNIVERSAL PROXY CARD AND ALL OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY AS THEY CONTAIN IMPORTANT INFORMATION ABOUT THE ANNUAL MEETING. The Definitive Proxy Statement contains information regarding the identity of the participants, and their direct and indirect interests, by security holdings or otherwise, in the Company’s securities and can be found in the section titled “Principal Stockholders” of the Definitive Proxy Statement and available here. Information regarding subsequent changes to their holdings of the Company’s securities can be found in the SEC filings on Forms 3, 4, and 5, which are available on the Company’s website available here or through the SEC’s website at www.sec.gov. Stockholders will be able to obtain the Definitive Proxy Statement, any amendments or supplements thereto and other documents filed by the Company with the SEC at no charge at the SEC’s website at www.sec.gov. Copies will also be available at no charge at the Company’s website at https://aimimmuno.com/sec-filings/. Exhibit 1 ISS Recommends AIM ImmunoTech Shareholders Vote “FOR” Company Nominees Nancy K. Bryan and Dr. William M. Mitchell ISS Finds That Activist Group’s Plan is “Limited” and Does Not Justify Control of the Board ISS Notes Activist Group Nominee Robert L. Chioini “Does Not Appear to Be an Appropriate Choice for the AIM Board” Given His Track Record at Rockwell Medical and Ties to Securities Law Felons ISS Also Recommends Against Election of Activist Group Nominee Todd A. Deutsch AIM Highlights $15 Million+ Investment Partnership Between Activist Group Nominees Ted Kellner and Paul Swe

View Full Filing

View this DEFA14A filing on SEC EDGAR